EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm

Michael A Hast, Amanda M Kong iD, Shaina Desai, Soo Back iD, Sahar Syed, Jordan Holmes

Toxins · 2024

DOI: 10.3390/toxins16080362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2024. Verfasst von Michael A Hast und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merz Therapeutics, Raleigh, NC 27615, USA. Hauptthemen laut MEDLINE: Hemifacial Spasm, Blepharospasm, Torticollis, Botulinum Toxins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merz (Germany), Merz Therapeutics GmbH, Frankfurt am Main, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Movement disorders such as cervical dystonia, blepharospasm, and hemifacial spasm negatively impact the quality of life of people living with these conditions. Botulinum toxin (BoNT) injections are commonly used to treat these disorders. We sought to describe patient characteristics, BoNT utilization, and potential adverse events (AEs) among patients with cervical dystonia, blepharospasm, and hemifacial spasm using Optum’s de-identified Clinformatics® Data Mart Database. Patients were required to have a diagnosis of the specific condition plus evidence of treatment with BoNT between 8/1/2010 and 5/31/2022. Cervical dystonia patients were commonly females (76%) and aged 45 and older (78%); both blepharospasm and hemifacial spasm patients were commonly females (both 69%) and aged 65 and older (61% and 56%, respectively). Anticholinergics were commonly used (65–82% across cohorts), as were peripheral muscle relaxants for cervical dystonia patients specifically (31%). The median number of injections per year was 2 with the median weeks between injections being between 13 and 15. Of the AEs evaluated, dyspnea was identified frequently across all the cohorts (14–20%). The findings were similar for different BoNT formulations. More research is needed to thoroughly describe BoNT utilization, such as the doses injected, and to optimize treatment for patients with these conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemifacial SpasmBlepharospasmTorticollisBotulinum ToxinsHumansFemaleAgedMiddle AgedMaleAdultNeuromuscular AgentsTreatment Outcome

Stichwörter der Autor:innen

adverse eventsblepharospasmbotulinum toxincervical dystoniahemifacial spasmmovement disorderstreatment utilization

Substanzen

Botulinum ToxinsNeuromuscular Agents

Autor:innen und Institutionen

  • Merz Therapeutics, Raleigh, NC 27615, USA.
  • Aetion, New York, NY 10001, USA.

ORCID-Profile: Amanda M Kong, Soo Back

Förderung

  • Merz (Germany)
  • Merz Therapeutics GmbH, Frankfurt am Main, Germany

Zitieren

APA

Hast, M. A., Kong, A. M., Desai, S., Back, S., Syed, S., & Holmes, J. (2024). Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm. Toxins. https://doi.org/10.3390/toxins16080362

Vancouver

Hast MA, Kong AM, Desai S, Back S, Syed S, Holmes J. Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm. Toxins. 2024. doi:10.3390/toxins16080362

BibTeX
@article{Hast2024,
  author = {Hast, Michael A and Kong, Amanda M and Desai, Shaina and Back, Soo and Syed, Sahar and Holmes, Jordan},
  title = {Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm},
  journal = {Toxins},
  year = {2024},
  doi = {10.3390/toxins16080362}
}
Kostenlos starten →